RU2233170C2 - Композиция контролированного высвобождения, включающая gnrh-ii - Google Patents

Композиция контролированного высвобождения, включающая gnrh-ii Download PDF

Info

Publication number
RU2233170C2
RU2233170C2 RU2001118040/15A RU2001118040A RU2233170C2 RU 2233170 C2 RU2233170 C2 RU 2233170C2 RU 2001118040/15 A RU2001118040/15 A RU 2001118040/15A RU 2001118040 A RU2001118040 A RU 2001118040A RU 2233170 C2 RU2233170 C2 RU 2233170C2
Authority
RU
Russia
Prior art keywords
xaa
polymer
osteoporosis
peptide
composition according
Prior art date
Application number
RU2001118040/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2001118040A (ru
Inventor
Стив КВИ (GB)
Стив КВИ
Карен АКИНСАНЬЯ (GB)
Карен АКИНСАНЬЯ
Аманда ХЕЙВАРД (GB)
Аманда ХЕЙВАРД
Original Assignee
Ферринг Б В
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ферринг Б В filed Critical Ферринг Б В
Publication of RU2001118040A publication Critical patent/RU2001118040A/ru
Application granted granted Critical
Publication of RU2233170C2 publication Critical patent/RU2233170C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2001118040/15A 1998-12-03 1999-12-02 Композиция контролированного высвобождения, включающая gnrh-ii RU2233170C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9826662.0 1998-12-03
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation

Publications (2)

Publication Number Publication Date
RU2001118040A RU2001118040A (ru) 2003-04-20
RU2233170C2 true RU2233170C2 (ru) 2004-07-27

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001118040/15A RU2233170C2 (ru) 1998-12-03 1999-12-02 Композиция контролированного высвобождения, включающая gnrh-ii

Country Status (22)

Country Link
EP (1) EP1140133A1 (xx)
JP (1) JP2002531411A (xx)
KR (1) KR20010089538A (xx)
CN (1) CN1332635A (xx)
AU (1) AU770676B2 (xx)
BR (1) BR9915943A (xx)
CA (1) CA2353798A1 (xx)
CZ (1) CZ20011893A3 (xx)
EE (1) EE200100293A (xx)
GB (1) GB2344287A (xx)
HR (1) HRP20010421A2 (xx)
HU (1) HUP0104943A3 (xx)
IL (1) IL143496A0 (xx)
MX (1) MXPA01005543A (xx)
NO (1) NO20012636L (xx)
NZ (1) NZ511984A (xx)
PL (1) PL348575A1 (xx)
RU (1) RU2233170C2 (xx)
SK (1) SK7552001A3 (xx)
TR (1) TR200102273T2 (xx)
WO (1) WO2000032218A1 (xx)
ZA (1) ZA200104530B (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909814B1 (en) 2005-07-26 2015-06-24 Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) Peptides for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2011056572A1 (en) 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
PE20140186A1 (es) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
US9415123B2 (en) 2011-10-10 2016-08-16 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
KR20140097151A (ko) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
MX2014015205A (es) 2012-06-14 2015-08-14 Ambrx Inc Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
CA2877127A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
JP6311708B2 (ja) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
US20180170992A1 (en) 2015-01-26 2018-06-21 The University Of Chicago CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
CN104789524A (zh) * 2015-04-30 2015-07-22 四川大学 骨质疏松大鼠原代成骨细胞分离培养方法及应用
US20180201937A1 (en) 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
KR20190117541A (ko) * 2017-01-20 2019-10-16 이뮨 시스템 레귤레이션 홀딩 에이비 신규 화합물 (이뮤노렐린)
MX2020000190A (es) 2017-06-30 2020-07-22 Amgen Inc Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
CR20200099A (es) 2017-08-03 2020-07-24 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
EP3826667B1 (en) 2017-09-18 2024-04-17 The Regents of the University of California Claudin6 antibodies and methods of treating cancer
UY38049A (es) 2018-01-12 2019-07-31 Amgen Inc Anti-pd-1 anticuerpos y métodos de tratamiento
WO2020055913A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of reducing- c-reactive protein and/or treating cardiovascular disease
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
CN114206934A (zh) 2019-03-20 2022-03-18 加利福尼亚大学董事会 密封蛋白-6双特异性抗体
CN112955181A (zh) * 2019-03-26 2021-06-11 新型医药公司 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物
CA3136496A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
CA3132656A1 (en) 2019-04-30 2020-11-05 Instituto De Medicina Molecular Joao Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
AU2020303986A1 (en) 2019-06-24 2021-12-09 Amgen Inc. Inhibition of SIRP-gamma for cancer treatment
EP4021454A1 (en) 2019-08-30 2022-07-06 Research Institute at Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
JP2024504696A (ja) 2021-01-20 2024-02-01 バイオアントレ エルエルシー Ｃｔｌａ４結合性タンパク質およびがんを処置する方法
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
DE3414595A1 (de) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt Verwendung von gonadoliberin und gonadoliberinagonisten zur behandlung klimakterischer beschwerden
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
NO302481B1 (no) * 1990-10-16 1998-03-09 Takeda Chemical Industries Ltd Polymer for et preparat med forlenget frigjöring, samt preparat med forlenget frigjöring
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AU3388597A (en) * 1996-06-13 1998-01-07 University Of Cape Town Human type ii gonadotropin-releasing hormone receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Биохимия гормонов и гормональная регуляция. /Под ред. H.А.Юдаева. - М.: Наука, 1976, с.127-143. *

Also Published As

Publication number Publication date
MXPA01005543A (es) 2003-07-14
KR20010089538A (ko) 2001-10-06
AU770676B2 (en) 2004-02-26
HUP0104943A3 (en) 2002-08-28
IL143496A0 (en) 2002-04-21
NO20012636D0 (no) 2001-05-29
PL348575A1 (en) 2002-06-03
EP1140133A1 (en) 2001-10-10
NZ511984A (en) 2002-11-26
CZ20011893A3 (cs) 2002-05-15
BR9915943A (pt) 2001-08-21
ZA200104530B (en) 2002-06-04
JP2002531411A (ja) 2002-09-24
WO2000032218A1 (en) 2000-06-08
SK7552001A3 (en) 2002-02-05
CA2353798A1 (en) 2000-06-08
NO20012636L (no) 2001-07-12
CN1332635A (zh) 2002-01-23
GB2344287A (en) 2000-06-07
EE200100293A (et) 2002-08-15
HUP0104943A2 (en) 2002-06-29
HRP20010421A2 (en) 2002-06-30
TR200102273T2 (tr) 2001-12-21
AU1573200A (en) 2000-06-19
GB9826662D0 (en) 1999-01-27

Similar Documents

Publication Publication Date Title
RU2233170C2 (ru) Композиция контролированного высвобождения, включающая gnrh-ii
JP2621970B2 (ja) 極く僅かのヒスタミンを放出するホルモン放出黄体形成ホルモンの効果的拮抗物質
US5084555A (en) An octapeptide bombesin analog
EP0309297B1 (en) Therapeutic peptides
AU638423B2 (en) Therapeutic peptides
US5244883A (en) Nonapeptide bombesin antagonists
JPH07507330A (ja) ポリペプチドのボンベシン拮抗物質
UA68407C2 (en) Antagonistic analogues of growth hormone releasing hormone (gh-rh) inhibiting activity of endogenous insulin-like growth factors
US7189692B2 (en) Synthetic peptides and pseudopeptides having osteogenic activity and pharmaceutical compositions containing the same
JP2000510112A (ja) ＴＧＦ―β拮抗物質としてのプロラクチンの使用方法
EP1124847B1 (en) Lhrh analogues for the treatment of osteoporosis
US5593965A (en) Anti-tumor effects of GnRH-III
Tziafas Induction of reparative dentinogenesis in vivo: a synthesis of experimental observations
EP0737691A1 (en) Bombesin analogs
US5439884A (en) Method of controlling fertilization using bombesin or its agonist
AU703865B2 (en) Bombesin analogs
AU622123C (en) Therapeutic peptides
RU2088592C1 (ru) Терапевтические пептиды или их фармацевтически приемлемые соли
NL8300413A (nl) Groeihormoon vrijstellend peptide.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20051203